Expansion of PIJ’s Medical and Research Applications and Industry–Academia Collaboration
First written in FY2016. 19 of 33 entries say "Restated". Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026RestatedAnnual report
「Pulse Injector® (hereinafter, “PIJ”) will continue promoting its expansion into multiple fields as a tool supporting R&D, primarily for university laboratories and the R&D departments of individual companies.」
The policy of expanding PIJ into multiple fields as an R&D support tool for university and corporate R&D departments has been reaffirmed. No new order or sales milestones are noted. - FY2026-H1RestatedAnnual report
「Pulse Injector® (hereinafter, “PIJ”) will continue promoting its expansion into multiple fields as a tool supporting R&D, primarily for university laboratories and the R&D departments of individual companies.」
The policy of expanding PIJ into multiple fields as an R&D support tool for university laboratories and corporate R&D departments has been reaffirmed. No new order or sales milestones are noted. - FY2025RestatedAnnual report
「Pulse Injector® (hereinafter, “PIJ”) will continue promoting its expansion into multiple fields as a tool supporting R&D, primarily for university laboratories and the R&D departments of individual companies.」
The policy of expanding PIJ into multiple fields as an R&D support tool for university and corporate R&D departments has been reaffirmed. - FY2025-H1RestatedAnnual report
「PIJ will continue promoting its expansion into multiple fields as a tool supporting R&D, primarily for university laboratories and the R&D departments of individual companies.」
The policy of expanding PIJ into multiple fields as an R&D support tool, primarily for university and corporate R&D departments, has been reaffirmed. - FY2024-Q1RestatedAnnual report
「Pulse Injector® (hereinafter, “PIJ”) is actively approaching university laboratories and the R&D departments of individual companies by using web conferences and visiting customers. We will continue promoting its expansion into multiple fields as a tool supporting R&D.」
Approaches to university and corporate R&D departments using web conferences and customer visits, as well as PIJ’s expansion into multiple fields, are continuing. - FY2023RestatedAnnual report
「Pulse Injector® (hereinafter, “PIJ”) is actively approaching university laboratories and the R&D departments of individual companies by using web conferences and visiting customers. We will continue promoting its expansion into multiple fields as a tool supporting R&D.」
Approaches to university and corporate R&D departments through web conferences and customer visits, as well as PIJ’s expansion into multiple fields, are continuing. - FY2023-Q3RestatedAnnual report
「Pulse Injector® (hereinafter, “PIJ”) is actively approaching university laboratories and the R&D departments of individual companies by using web conferences and visiting customers. We will continue promoting its expansion into multiple fields as a tool supporting R&D.」
In addition to using web conferences, customer visits are being conducted, and approaches to university and corporate R&D departments and PIJ’s expansion into multiple fields are continuing. - FY2023-Q2RestatedAnnual report
「Pulse Injector® (hereinafter, “PIJ”) is actively approaching university laboratories and the R&D departments of individual companies by using web conferences and visiting customers. We will continue promoting its expansion into multiple fields as a tool supporting R&D.」
In addition to using web conferences, customer visits are being conducted, and approaches to university and corporate R&D departments and PIJ’s expansion into multiple fields are continuing. - FY2023-Q1AdvancedAnnual report
「Pulse Injector® (hereinafter, “PIJ”) is actively approaching university laboratories and the R&D departments of individual companies by using web conferences and visiting customers. We will continue promoting its expansion into multiple fields as a tool supporting R&D.」
In addition to using web conferences, customer visits are being conducted to advance approaches to university and corporate R&D departments. The means of conducting sales activities have become more specific. - FY2022AdvancedAnnual report
「Pulse Injector® (hereinafter, “PIJ”) actively approached university laboratories and the R&D departments of individual companies, primarily through web conferences, as the R&D activities of universities and customer companies recovered fully. As a result, it increased substantially year on year.」
Against the backdrop of recovering R&D activities at universities and customer companies, approaches were conducted primarily through web conferences, and PIJ-related sales increased substantially year on year. - FY2022-Q3RestatedAnnual report
「Pulse Injector® (hereinafter, “PIJ”) is actively approaching university laboratories and the R&D departments of individual companies, with web conferences becoming the primary means as the R&D activities of universities and customer companies recover fully. We will continue promoting its expansion into multiple fields as a tool supporting R&D.」
Against the backdrop of recovering R&D activities at universities and customer companies, proactive approaches conducted primarily through web conferences and PIJ’s expansion into multiple fields are continuing. - FY2022-Q2RestatedAnnual report
「Pulse Injector® (hereinafter, “PIJ”) is actively approaching university laboratories and the R&D departments of individual companies, with web conferences becoming the primary means as the R&D activities of universities and customer companies recover fully. We will continue promoting its expansion into multiple fields as a tool supporting R&D.」
Based on the recovery of R&D activities at universities and customer companies, approaches to laboratories and companies, primarily through web conferences, and PIJ’s expansion into multiple fields are continuing. - FY2022-Q1AdvancedAnnual report
「Pulse Injector® (hereinafter, “PIJ”) is actively approaching university laboratories and the R&D departments of individual companies, with web conferences becoming the primary means as the R&D activities of universities and customer companies recover fully. We will continue promoting its expansion into multiple fields as a tool supporting R&D.」
As the R&D activities of universities and customer companies recover fully, proactive approaches to university and corporate R&D departments are being conducted primarily through web conferences. Progress in activities aimed at expanding PIJ into multiple fields is noted. - FY2021-Q3AdvancedAnnual report
「Pulse Injector® (hereinafter, “PIJ”) is actively approaching university laboratories and the R&D departments of individual companies, with web conferences becoming the primary means as universities and customer companies fully restart their R&D activities. We will continue promoting its expansion into multiple fields as a tool supporting R&D.」
As universities and customer companies fully restart their R&D activities, proactive approaches are being conducted primarily through web conferences. Activities aimed at expanding PIJ into multiple fields are progressing. - FY2021-Q2AdvancedAnnual report
「Pulse Injector® (hereinafter, “PIJ”) is on the road to recovery as customers resume their R&D activities, and is approaching university laboratories and the R&D departments of individual companies, primarily via the web. We will continue promoting its expansion into multiple fields as a tool supporting R&D.」
PIJ is described as being on the road to recovery as corporate customers resume their R&D activities, with approaches to university and corporate R&D departments conducted primarily via the web. - FY2021-Q1SoftenedAnnual report
「Pulse Injector® (hereinafter, “PIJ”) is approaching university laboratories and the R&D departments of individual companies, although customer development-cost reductions and the discontinuation of research projects have had an impact. We will continue promoting its expansion into multiple fields as a tool supporting R&D.」
Approaches to university and corporate R&D departments and expansion into multiple fields are continuing, while the impact of customer development-cost reductions and the discontinuation of research projects is explicitly noted, indicating a weaker environment for expansion. - FY2020SoftenedAnnual report
「Pulse Injector® (hereinafter, “PIJ”) has strengthened follow-up with university laboratories and the R&D departments of individual companies through proactive approaches via trade shows and specialist websites. Sales driven mainly by continuing demand from existing users progressed steadily. However, users have been tending to reduce their R&D budgets, resulting in weak orders for new equipment and sluggish sales growth.」
Although sales driven by demand from existing users are described as steady, orders for new equipment have been weak due to reductions in R&D budgets, weakening the wording regarding sales growth. - FY2020-Q3RestatedAnnual report
「Pulse Injector® (hereinafter, “PIJ”) continues to receive solid inquiries from university laboratories and the R&D departments of individual companies through trade shows and specialist websites for research products. We will continue promoting its expansion into multiple fields as a tool supporting R&D.」
Inquiries from university and corporate R&D departments remain solid, and the policy of expanding PIJ into multiple fields as an R&D support tool has been reaffirmed. - FY2020-Q2SoftenedAnnual report
「Pulse Injector® (hereinafter, “PIJ”) continues to receive solid inquiries from university laboratories and the R&D departments of individual companies through trade shows and specialist websites for research products. We will continue promoting its expansion into multiple fields as a tool supporting R&D.」
Compared with the previous quarter’s wording that “inquiries increased,” this time the wording is that inquiries “remain solid,” indicating a weaker description of inquiry growth. Meanwhile, the policy of expansion into multiple fields continues. - FY2020-Q1RestatedAnnual report
「Pulse Injector® (hereinafter, “PIJ”) has seen an increase in inquiries from university laboratories and the R&D departments of individual companies through trade shows and other channels. We will continue promoting its expansion into multiple fields as a tool supporting R&D.」
Inquiries from university and corporate R&D departments have increased through trade shows and other channels, and the policy of expanding PIJ into multiple fields has been reaffirmed. - FY2019AdvancedAnnual report
「Through proactive approaches via trade shows and specialist websites featuring technology, Pulse Injector® strengthened follow-up with university laboratories and the R&D departments of individual companies. As a result of promoting expansion into the creation of new domestic industries in collaboration with customers, it received numerous orders, primarily for equipment, contributing to sales.」
Approaches through trade shows and specialist websites, together with collaboration with customers, resulted in numerous orders, primarily for equipment, contributing to sales. - FY2019-Q3AdvancedAnnual report
「Pulse Injector® (hereinafter, “PIJ”) has continued to see steady growth in orders from major corporate laboratories and universities. We will continue promoting its expansion into multiple fields as a tool supporting R&D.」
Orders from major corporate laboratories and universities have increased steadily, and progress has been made in expanding PIJ into multiple fields. - FY2019-Q2RestatedAnnual report
「Pulse Injector® (hereinafter, PIJ) continues to receive inquiries from university laboratories and corporate research and development departments. We will continue promoting expansion into multiple fields as a tool supporting research and development.」
Inquiries from university and corporate R&D departments continue, and the policy of expanding PIJ into multiple fields as an R&D support tool has been reaffirmed. - FY2019-Q1AdvancedAnnual report
「Pulse Injector® (hereinafter, PIJ) has seen an increase in inquiries from university laboratories and corporate research and development departments through exhibitions and other channels, contributing to sales of equipment and other products. We will continue promoting expansion into multiple fields as a tool supporting research and development.」
It is stated that inquiries from university and corporate research and development departments through exhibitions and other channels increased, contributing to sales of equipment and other products. - FY2018RestatedAnnual report
「Pulse Injector® is easy to handle because it has a single nozzle and can accommodate a wide range of liquids because of its excellent chemical resistance, so we will continue expanding sales in research and development fields. We believe it has gained recognition mainly among corporate laboratories, universities and laboratories at other research institutions, including regional and government organizations. Recently, inkjet technology has also been applied to industrial uses such as printable electronics, 3D printing and textile printing, with basic research actively under way. It is being used not only in regenerative and preventive medicine but also in biotechnology fields such as diagnostic and personalized medicine.」
The company has reconfirmed its policy of expanding PIJ sales in research and development fields, collaborating with universities, companies and research institutions, and pursuing applications in medical, biotechnology and industrial fields. - FY2018-Q3RestatedAnnual report
「Pulse Injector® (hereinafter, PIJ) is strengthening follow-up with university laboratories and corporate research and development departments and promoting expansion into the creation of new domestic industries in collaboration with customers.」
For PIJ, the company continues to strengthen follow-up with university and corporate research and development departments and promote expansion into the creation of new domestic industries through collaboration with customers. - FY2018-Q2RestatedAnnual report
「Pulse Injector® (hereinafter, PIJ) is strengthening follow-up with university laboratories and corporate research and development departments and promoting expansion into the creation of new domestic industries in collaboration with customers.」
The company continues to strengthen follow-up with university and corporate research and development departments and expand PIJ through collaboration with customers. - FY2018-Q1RestatedAnnual report
「Pulse Injector® (hereinafter, PIJ) is strengthening follow-up with university laboratories and corporate research and development departments and promoting expansion into the creation of new domestic industries in collaboration with customers.」
For PIJ, the company continues to strengthen follow-up with university and corporate research and development departments and promote expansion into the creation of new domestic industries through collaboration with customers. - FY2017AdvancedAnnual report
「Pulse Injector® has gained recognition mainly among university laboratories and laboratories at other research institutions, including regional and government organizations. Recently, it has been used not only in regenerative and preventive medicine but also in diagnostic and personalized medicine. Although there remain many challenges to overcome before research conducted in collaboration with venture companies, universities and other research institutions can be put into practical use, this is a priority field as a market that can lead to the creation of new domestic industries and innovation.」
For PIJ, the company reported applications not only in regenerative and preventive medicine but also in diagnostic and personalized medicine, and is also advancing collaboration with universities, research institutions and venture companies. - FY2017-Q3RestatedAnnual report
「Pulse Injector® (hereinafter, PIJ) has newly entered into a partnership with a distributor that sells biotechnology equipment through catalogs. We will strengthen follow-up with university laboratories and corporate research and development departments to develop new customers, while promoting expansion into the creation of new domestic industries in collaboration with universities and companies.」
The company continues its partnership with a distributor that sells biotechnology equipment through catalogs, follow-up with university and corporate research and development departments, and new customer development. - FY2017-Q2RestatedAnnual report
「Pulse Injector® (hereinafter, PIJ) has newly entered into a partnership with a distributor that sells biotechnology equipment through catalogs. We will strengthen follow-up with university laboratories and corporate research and development departments to develop new customers, while promoting expansion into the creation of new domestic industries in collaboration with universities and companies.」
The company continues its partnership with a distributor that sells biotechnology equipment through catalogs, follow-up with university and corporate research and development departments, and new customer development. - FY2017-Q1AdvancedAnnual report
「Pulse Injector® (hereinafter, PIJ) has newly entered into a partnership with a distributor that sells biotechnology equipment through catalogs. We will strengthen follow-up with university laboratories and corporate research and development departments to develop new customers, while promoting expansion into the creation of new domestic industries in collaboration with universities and companies.」
PIJ has entered into a new partnership with a distributor that sells biotechnology equipment through catalogs and is strengthening follow-up with university and corporate research and development departments. - FY2016First statedAnnual report
「We will promote development in regenerative and preventive medicine by collaborating with universities, public research institutions and other organizations. We will also actively promote the development of modules and devices through collaboration with companies in other industries.」
For PIJ, measures to expand applications and product formats through collaboration with universities, public research institutions and companies in the medical field.